

- Klin. 1973, 68: 216-219. – 11. Fitzgerald DJ., Roy L., Catella F., Fitzgerald GA. Platelet activation in unstable coronary artery disease. *N. Engl. J. Med.* 1986, 315: 983-989. – 12. Gavin JB., Maxwell L., Edgar SG. Microvascular involvement in cardiac pathology. *J. Mol. Cell. Cardiol.* 1998, 30: 2531-2540. – 13. Gawaz M., Ott I., Reininger AJ., Neumann FJ. Effects of magnesium on platelet aggregation and adhesion: magnesium modulates surface expression of glycoproteins on platelets in vitro and ex vivo. *Thromb. Haemost.* 1994, 72: 912-918. – 14. Goudevenos J., Tselepis AD., Tsoukatos D., Grekas G., Kritikakos J., Sideris D. *Eur. Heart J.* 1995, 16: 1036-1043. – 15. Hardy E., Glenn J., Heptinstall S., Rubin P.C., Horn E.H. Magnesium modifies the responses of platelets to inhibitory agents which acts via cAMP. *Thromb. Haemost.* 1995, 74, 1132-1137. – 16. Heijnen JB., Coronel R., Van Zwieten PA. The effects of calcium antagonists on extracellular potassium accumulation during global ischemia in isolated perfused rat hearts. *Cardiovasc. Drugs Ther.* 1991 5: 1035-1041. – 17. Heptinstall S. The use of a chelating ion-exchange resin to evaluate the effects of the extracellular calcium concentration on adenosine diphosphate induced aggregation on human blood platelets. *Thromb. Haemost.* 1976, 36: 208-220. – 18. Herrman RG., Lacefield WB., Crve VG. Effect of ionic calcium and magnesium on human platelet aggregation. *Proc. Soc. Exp. Biol. Med.* 1970, 135: 100. – 19. Hwang DL., Yen CF., Nadler JL. Effect of extracellular magnesium on platelet activation and intracellular calcium mobilization. *Am. J. Hypertension*, 1992, 5: 700-706. – 20. Iseri LT., French JH. Magnesium: Nature's physiologic calcium blocker. *Am. Heart J.* 1984, 108: 188-193. – 21. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group: ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected myocardial infarction. *Lancet*, 1995, 345: 669-685. – 22. Kanda T., Hirao Y., Oshima S. et al. Interleukin-8 as a sensitive marker of unstable coronary artery disease. *Am. J. Cardiol.* 1996, 77: 304-307. – 23. Keller L.: A magnézium anyagcsere kóreltani és klinikai jelentősége. *Orv. Hetil.* 1964, 105: 1585-1589. – 24. Kimura T., Yasue H., Sakaino N., Rokutanda M., Jougasaki M., Araki H. Effects of magnesium on tone of isolated human coronary arteries. Comparison with diltiazem and nitroglycerin. *Circulation*, 1989, 79: 1118-1124. – 25. Kiss Z., Bárdos J., Domokos M., Tóth M., Sepp J. Beneficial effect of intravenous magnesium sulphate in acute myocardial infarction. *Magn. Res.* 1992, 5: 242-243. – 26. Kiyak JH., Zerbino DD. Pathogenesis and morphogenesis of microcirculatory disorders in myocardial infarction: clinical and ultrastructural examination. *Polish J. Pathol.* 1996, 47: 27-32. – 27. Kondo H., Tatsumi N.: Anti-coagulation and antiplatelet effects of magnesium sulphate. *Blood*, 2002, 111(11): Abstr. 3868. – 28. Kristensen SD., Bath PMW., Martin JF. Differences in bleeding time, aspirin sensitivity and adrenaline between acute myocardial infarction and unstable angina. *Cardiovasc. Res.* 1990, 24: 19-23. – 29. Ma XL., Tsao PS., Viehman GE., Lefer AM. Neutrophil-mediated vasoconstriction and endothelial dysfunction in low-flow perfusion-reperfused cat coronary artery. *Circ. Res.* 1990, 69: 95-106. – 30. Michaels AD., Gibson CM., Barron HV. Microvascular dysfunction in acute myocardial infarction: focus on the roles of platelet and inflammatory mediators in the no-reflow phenomenon. *Am. J. Cardiol.* 2000, 85: 50B-60B. – 31. Moake JL., Turner NA., Stathopoulos NA., Nolasco LH., Hellums JD. Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate, and is resistant to aspirin. *Blood*, 1998, 71: 1366-1374. – 32. Montalescot G., Maclouf J., Drobinski G. et al. Lack of platelet-activating factor release during reversible myocardial ischaemia. *Eur. Heart J.* 1992, 13: 1641-1644. – 33. Ravn HB., Kristensen SD., Hjortdal VE. et al. Early administration of intravenous magnesium inhibits arterial thrombus formation. *Arterioscler. Thromb. Vasc. Biol.* 1997, 17: 3620-3625. – 34. Ravn HB., Vissing H., Kristensen SD., Husted SE. Magnesium inhibits platelet activity – an in vitro study. *Thromb. Haemost.* 1996, 76: 88-93. – 35. Rayssiguier Y., Gueux E.: Magnesium and lipids in cardiovascular disease. *J. Am. Coll. Nutr.* 1986 5: 507-519. – 36. Redwood SR., Bashir Y., Huang J., Leatham EW., Kaski JC., Camm AJ. Effect of magnesium sulphate in patient with unstable angina: a double blind, randomized, placebo-controlled study. *Eur. Heart J.* 1997, 18: 1269-1277. – 37. Roth A., Eshchar Y., Keren G., Kerbel S., Harsa A., Villa Y., Laniado S., Miller Hl. Effect of magnesium on restenosis after percutaneous transluminal coronary angioplasty: a clinical and angiographic evaluation in a randomized patient population. *Eur. Heart J.* 1994, 15: 1164-1173. – 38. Rukshin V., Azarbal B., Shah PK. et al. Intravenous magnesium in experimental stent thrombosis in swine. *Arterioscler. Thromb. Vasc. Biol.* 2001, 21: 1544-1549. – 39. Rukshin V., Shah PK., Cercek B., Finkelstein A., Tsang V., Kaul S. Comparative antithrombotic effects of magnesium sulfate and the platelet glycoprotein IIb/IIIa inhibitors tirofiban and eptifibatid in a canine model of stent thrombosis. *Circulation*, 2002, 105: 1970-1975. – 40. Serebruany VL., Herzog WR., Gurbel PA.: Serial changes of natural antithrombotics during myocardial ischemia-reperfusion in swine. Effects of magnesium, diltiazem, and a novel Mac-1 inhibitor. *Blood. Coag. Fibrinol.* 1996, 7: 632-640. – 41. Serebruany VL., Schlossberg ML., Edenbaum LR., Herzog WR., Gurbel PA. Intracoronary magnesium and diltiazem affect to a similar extent certain hemostatic factors during acute myocardial infarction in swine. *Pharmacology*, 1996, 53: 224-233. – 42. Sobel M., McNeill PM., Carlson PL. et al. Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. *J. Clin. Invest.* 1991, 87: 1787-1793. – 43. Staatz WD., Rajpara SM., Wayner EA., Carter WG., Santoro SA. The membrane glycoprotein Ia-IIa (VLA-2) complex mediates the Mg⁺⁺-dependent adhesion of platelets to collagen. *J. Cell. Biol.* 1989, 108: 1917-1924. – 44. Tselepis AD., Tsoukatos D., Droudes C., Donas A., Evangelou A. Platelet response to the aggregatory effect of platelet activating factor (PAF) ex vivo in patients with acute myocardial infarction. *Eur. J. Clin. Invest.* 1991, 21: 490-496. – 45. van Diest R., Appels A.: Vital exhaustion: behavioural and biological correlates. *Curr. Opin. Psychiatry*, 2002, 15: 639-641. – 46. Ward BJ., McCarthy A. Endothelial cell „swelling” is ischemia and reperfusion. *J. Mol. Cell. Cardiol.* 1995, 27: 1293-1300. – 47. Woods KL., Fletcher S., Roffe C. et al. Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). *Lancet*, 1992, 339: 1553-1558. – 48. Zimmerman GA., McIntyre TM., Mehra M., Prescott SM. Endothelial cell-associated platelet-activating factor: a novel mechanism for signaling intercellular adhesion. *J. Cell. Biol.* 1990, 110: 529-540.